Thymagen dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 7 published studies are one click away.
Human trials Bioregulators Also called Thymogen, Glu-Trp, EW dipeptide, oglufanide, IM862
Common use ranges
From user guides and clinic write-ups. No drug label exists, and no study has tested these amounts in people. The two community guides differ by about 200 times, from micrograms 3 times a week to 10 to 20 mg a day. Treat every number here as unsettled. No approved label exists.
Sources disagree, or there are very few. The amounts below come from a small number of guides, and they do not line up well. Treat every number on this page as uncertain, and check each source yourself.
- Half-life
- Not measured in any published study
- How it is taken
- Shot under the skin (subcutaneous), or oral capsule
- How long people use it
- Sources split. One gives daily courses of 10 to 20 days, 2 to 3 times a year. Another gives 3 shots a week for 8 to 16 weeks.
- Mixing used for the units
- 10 mg vial + 2 mL water. 1 unit on a U-100 insulin syringe = 50 mcg.
Pick your vial size and how much water you add. The units below change to match.
10 mg vial + 2 mL water: 1 unit = 50 mcg
| Tier | Each dose | Syringe units10 mg vial + 2 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Starting [1] | 10 mcg | 0.2 units 0.00 mL | 3x a week | 10 to 20 mcg under the skin 3 times a week for the first 2 weeks. | 6+ weeks |
| Typical [2] | 50 mcg | 1 units 0.01 mL | 3x a week | 20 to 50 mcg under the skin 3 times a week as the working amount. | 6+ weeks |
| Higher [3] | 10 mg | over 100 units 2.00 mL | once a day | 10 to 20 mg under the skin or into the muscle once a day for 10 to 20 days. | 1 day |
Good to know
- Also spelled Thymogen.
- Not the same as Thymalin, a different thymus peptide with its own 10 mg, 10 day course.
- Oral and nasal forms exist, but no guide gives an amount for them.
Sources for these amounts
- Starting: MyPeptideMatch, Thymagen dosage guide
- Typical: MyPeptideMatch, Thymagen dosage guide
- Higher: Peptide DB, Thymogen
How long people use it: Peptide DB, Thymogen · MyPeptideMatch, Thymagen dosage guide · Khavinson bioregulator guide (IPS News)
Half-life: Deplanque et al, Br J Cancer 2004 (phase II, open full text, no PK reported)
Take the Thymagen chart with you
Get a one-page printable chart for Thymagen, with the syringe units for each vial and water mix. We can also email you when a new Thymagen study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 7 published studies
Amounts given to people in studies
How it was given: In the nose
Western trials ran it as IM862 for Kaposi sarcoma and kidney cancer. The phase III trial found it no better than placebo.
Amounts given to animals in studies
Read this first. A 2011 Russian abstract reports 100 mg in the nose once a day for 7 days, far above every other figure, so it was left out of the range. The 2005 phase III abstract calls IM862 L-glutamine L-tryptophan while other papers say L-Glu-L-Trp. Rat 10 and 100 microg/kg route and schedule are not in the abstract.
Every study used for this page
Proof grade: Human trials. Tested in randomized human trials. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 15598977Noy et al, J Clin Oncol 2005 | Human, 202 HIV patients with Kaposi sarcoma (104 IM862, 98 placebo), randomized double-blind | 5 mg | In the nose | Every other day | 24 weeks (median 19.5 weeks on drug) | No better than placebo. Shorter time to progression |
| PMID 10673512Tulpule et al, J Clin Oncol 2000 | Human, 44 adults with AIDS Kaposi sarcoma, randomized to two schedules | 5 mg | In the nose (drops) | 5 days on, 5 off (n = 18) or every other day (n = 26) | Repeated cycles until progression | 36% major responses. Mild headache, fatigue, tingling, nausea |
| PMID 15354209Deplanque et al, Br J Cancer 2004 | Human, 25 adults with metastatic kidney cancer, open phase II | 20 mg | In the nose | Three times a day | 8-week cycles | No objective responses. No drug-related grade 2 or 3 toxicity. Plasma VEGF fell |
| PMID 21957588Smirnov et al, Adv Gerontol 2011 | Human, elderly surgical cancer patients, randomized double-blind placebo-controlled (n not in abstract) | 100 mg | In the nose | Once a day | 7 days before surgery | Better cellular immunity and fewer post-op complications |
| PMID 10605346Medus et al, Voen Med Zh 1999 | Human, destructive lung tuberculosis (n not in abstract) | 1 ml of 1% solution per injection, 10 injections | Injection (type not in abstract) | Every 2 days | 2 courses over a 2 and 4 month treatment | Stimulated T cells, better tolerance of TB drugs |
| PMID 11707921Anisimov et al, Biogerontology 2000 | Rat, 76 outbred females from 5 months old (44 treated, 32 control) | 5 mcg per rat in 0.2 ml saline | Under the skin | 5 times a week | 12 months | Longest-lived 10% lived longer (1048 vs 949 days). Tumours 1.5 times lower |
| PMID 40442470Chulanova et al, Bull Exp Biol Med 2025 | Rat, hydrazine liver injury model (n not in abstract) | 10 and 100 mcg/kg | Not in abstract | Not in abstract | Not in abstract | 10 mcg/kg cut lipid peroxidation and helped liver repair. 100 mcg/kg added nothing more |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
What amounts of Thymagen were used in human studies?
In the studies listed here, people were given from 5 mg in the nose every other day, or 5 days on and 5 off up to 20 mg in the nose three times a day in 8-week cycles. The amount used most often was 5 mg in the nose every other day (24-week randomized trial, 202 patients). These are what study teams chose for their participants under supervision.
Where do these Thymagen numbers come from?
From 7 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Human trials.
How long does Thymagen stay in the body?
No published study has measured the half-life of Thymagen, so nobody knows exactly how long one dose stays in the blood.
Is this a recommendation for how much Thymagen to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.